HomeCompareABT vs DRI

ABT vs DRI: Dividend Comparison 2026

ABT yields 2.36% · DRI yields 3.02%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRI wins by $431.81M in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
DRI
DRI
● Live price
3.02%
Share price
$195.05
Annual div
$5.90
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$432.34M
Annual income
$406,525,727.38
Full DRI calculator →

Portfolio growth — ABT vs DRI

📍 DRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTDRI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + DRI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
DRI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
DRI
Annual income on $10K today (after 15% tax)
$257.11/yr
After 10yr DRIP, annual income (after tax)
$345,546,868.27/yr
At 15% tax rate, DRI beats the other by $345,267,412.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + DRI for your $10,000?

ABT: 50%DRI: 50%
100% DRI50/50100% ABT
Portfolio after 10yr
$216.44M
Annual income
$203,427,249.71/yr
Blended yield
93.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DRI right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
DRI
Analyst Ratings
38
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$225.33
+15.5% upside vs current
Range: $200.00 — $265.00
Altman Z
2.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
DRI buys
0
No recent congressional trades found for ABT or DRI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTDRI
Forward yield2.36%3.02%
Annual dividend / share$2.40$5.90
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%100%
Portfolio after 10y$533.6K$432.34M
Annual income after 10y$328,772.04$406,525,727.38
Total dividends collected$492.4K$430.43M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$137.67$225.33

Year-by-year: ABT vs DRI ($10,000, DRIP)

YearABT PortfolioABT Income/yrDRI PortfolioDRI Income/yrGap
1← crossover$11,084$384.43$11,305$604.97$221.00DRI
2$12,510$649.94$13,375$1,278.36$865.00DRI
3$14,505$1,118.82$17,138$2,826.91$2.6KDRI
4$17,499$1,978.53$25,108$6,770.65$7.6KDRI
5$22,364$3,640.59$45,407$18,541.07$23.0KDRI
6$31,026$7,096.70$111,259$62,674.02$80.2KDRI
7$48,215$15,016.56$406,092$287,044.64$357.9KDRI
8$87,182$35,592.30$2,392,840$1,958,321.72$2.31MDRI
9$191,446$98,161.15$24,128,817$21,568,477.53$23.94MDRI
10$533,619$328,772.04$432,343,561$406,525,727.38$431.81MDRI

ABT vs DRI: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

DRIConsumer Discretionary

Darden Restaurants, Inc., through its subsidiaries, owns and operates full-service restaurants in the United States and Canada. As of May 29, 2022, it owned and operated 1,867 restaurants, which included 884 under the Olive Garden brand, 546 under the LongHorn Steakhouse brand name, 172 under the Cheddar's Scratch Kitchen brand, 85 under the Yard House brand name, 62 under The Capital Grille brand, 45 under the Seasons 52 brand name, 42 under the Bahama Breeze brand, 28 under the Eddie V's Prime Seafood brand name, and 3 under the Capital Burger brand; and franchised 60 restaurants comprising 35 under the Olive Garden brand, 18 under the LongHorn Steakhouse brand name, 4 under the Cheddar's Scratch Kitchen brand, 2 under The Capital Grille brand name, and 1 under the Bahama Breeze brand.Darden Restaurants, Inc. was founded in 1968 and is based in Orlando, Florida.

Full DRI Calculator →
📬

Get this ABT vs DRI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.